Theodoros Foukakis

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BREAST CANCER RESEARCH AND TREATMENT. 2024;204(2):299-308

The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial.

Zhu Y; Zerdes I; Matikas A; Cruz IR; Bergqvist M; Elinder E; Bosch A; Lindman H; Einbeigi Z; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Hellstrom M; Johansson H; Wang K; Bergh JCS; Hatschek T; Foukakis T
Article: BREAST CANCER RESEARCH. 2024;26(1):24

Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.

Rönnlund C; Sifakis EG; Schagerholm C; Yang Q; Karlsson E; Chen X; Foukakis T; Weidler J; Bates M; Fredriksson I; Robertson S; Hartman J
Article: BREAST CANCER RESEARCH. 2024;26(1):4

Identification of a Notch transcriptomic signature for breast cancer.

Braune E-B; Geist F; Tang X; Kalari K; Boughey J; Wang L; Leon-Ferre RA; D'Assoro AB; Ingle JN; Goetz MP; Kreis J; Wang K; Foukakis T; Seshire A; Wienke D; Lendahl U
Article: ECLINICALMEDICINE. 2024;67:102335

Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths - a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden

Rodriguez-Wallberg KA; Kieler H; Foukakis T; Li J; Gissler M; Oberg AS; Bergh J; Lundberg FE
Article: BMJ OPEN. 2023;13(12):e078023

ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden-a phase III randomised double-blinded placebo-controlled study.

Rodriguez-Wallberg KA; Nilsson HP; Bergh J; Malmros J; Ljungman P; Foukakis T; Stragliotto CL; Friman EI; Linderholm B; Valachis A; Andersson A; Harrysson S; Vennström L; Frisk P; Mörse H; Eloranta S
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(33):5118-5130

Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial.

Pfeiler G; Hlauschek D; Mayer EL; Deutschmann C; Kacerovsky-Strobl S; Martin M; Meisel JL; Zdenkowski N; Loibl S; Balic M; Park H; Prat A; Isaacs C; Bajetta E; Balko JM; Bellet-Ezquerra M; Bliss J; Burstein H; Cardoso F; Fohler H; Foukakis T; Gelmon KA; Goetz M; Haddad TC; Iwata H; Jassem J; Lee S-C; Linderholm B; Los M; Mamounas EP; Miller KD; Morris PG; Munzone E; Gal-Yam EN; Ring A; Shepherd L; Singer C; Thomssen C; Tseng L-M; Valagussa P; Winer EP; Wolff AC; Zoppoli G; Machacek-Link J; Schurmans C; Huang X; Gauthier E; Fesl C; Dueck AC; DeMichele A; Gnant M; PALLAS Groups and Investigators
Article: JOURNAL OF CLINICAL INVESTIGATION. 2023;133(22):e166666

FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters.

Li M; Nishimura T; Takeuchi Y; Hongu T; Wang Y; Shiokawa D; Wang K; Hirose H; Sasahara A; Yano M; Ishikawa S; Inokuchi M; Ota T; Tanabe M; Tada K-I; Akiyama T; Cheng X; Liu C-C; Yamashita T; Sugano S; Uchida Y; Chiba T; Asahara H; Nakagawa M; Sato S; Miyagi Y; Shimamura T; Nagai LAE; Kanai A; Katoh M; Nomura S; Nakato R; Suzuki Y; Tojo A; Voon DC; Ogawa S; Okamoto K; Foukakis T; Gotoh N
Article: ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY. ANNUAL INTERNATIONAL CONFERENCE. 2023;2023:1-4

Multiresolution Self-Supervised Feature Integration via Attention Multiple Instance Learning for Histopathology Analysis.

Tsiknakis N; Tzoras E; Zerdes I; Manikis GC; Acs B; Hartman J; Hatschek T; Foukakis T; Marias K
Article: CLINICAL CANCER RESEARCH. 2023;29(3):532-540

Survival Outcomes, Digital TILs, and On-treatment PET/CT During Neoadjuvant Therapy for HER2-positive Breast Cancer: Results from the Randomized PREDIX HER2 Trial.

Matikas A; Johansson H; Grybäck P; Bjöhle J; Acs B; Boyaci C; Lekberg T; Fredholm H; Elinder E; Margolin S; Isaksson-Friman E; Bosch A; Lindman H; Adra J; Andersson A; Agartz S; Hellström M; Zerdes I; Hartman J; Bergh J; Hatschek T; Foukakis T
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2023;120(1):e2209856120

Breast cancer patient-derived whole-tumor cell culture model for efficient drug profiling and treatment response prediction.

Chen X; Sifakis EG; Robertson S; Neo SY; Jun S-H; Tong L; Hui Min AT; Lövrot J; Hellgren R; Margolin S; Bergh J; Foukakis T; Lagergren J; Lundqvist A; Ma R; Hartman J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2022;194(1):49-56

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study.

Boman C; Edman Kessler L; Bergh J; Matikas A; Foukakis T
Article: MOLECULAR ONCOLOGY. 2022;16(12):2413-2431

Integrated multi-omics profiling of high-grade estrogen receptor-positive, HER2-negative breast cancer.

Wang K; Li L; Franch-Expósito S; Le X; Tang J; Li Q; Wu Q; Bassaganyas L; Camps J; Zhang X; Li H; Foukakis T; Xiang T; Wu J; Ren G
Article: CANCERS. 2022;14(11):2615

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study.

Kjällquist U; Acs B; Margolin S; Karlsson E; Kessler LE; Garcia Hernandez S; Ekholm M; Lundgren C; Olsson E; Lindman H; Foukakis T; Matikas A; Hartman J
Article: NPJ BREAST CANCER. 2021;7(1):144

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study.

Zerdes I; Simonetti M; Matikas A; Harbers L; Acs B; Boyaci C; Zhang N; Salgkamis D; Agartz S; Moreno-Ruiz P; Bai Y; Rimm DL; Hartman J; Mezheyeuski A; Bergh J; Crosetto N; Foukakis T
Article: CANCERS. 2021;13(18):4655

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer.

Zerdes I; Karafousia V; Mezheyeuski A; Stogiannitsi M; Kuiper R; Moreno Ruiz P; Rassidakis G; Bergh J; Hatschek T; Foukakis T; Matikas A
Article: JAMA ONCOLOGY. 2021;7(9):1360-1367

Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.

Hatschek T; Foukakis T; Bjöhle J; Lekberg T; Fredholm H; Elinder E; Bosch A; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Azavedo E; Grybäck P; Hellström M; Johansson H; Maes C; Zerdes I; Hartman J; Brandberg Y; Bergh J
Article: ESMO OPEN. 2021;6(4):100217

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST).

Eriksson M; Reichardt P; Joensuu H; Krarup-Hansen A; Hagberg O; Hohenberger P; Hagberg H; Hansson L; Foukakis T; Pulkkanen K; Bauer S; Goplen D; Blach Rossen P; Sundby Hall K
Article: CLINICAL NUTRITION. 2021;40(5):3370-3378

Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study.

Wang K; Wu Q; Li Z; Reger MK; Xiong Y; Zhong G; Li Q; Zhang X; Li H; Foukakis T; Xiang T; Zhang J; Ren G
Article: ESMO OPEN. 2021;6(2):100076

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.

Matikas A; Wang K; Lagoudaki E; Acs B; Zerdes I; Hartman J; Azavedo E; Bjöhle J; Carlsson L; Einbeigi Z; Hedenfalk I; Hellström M; Lekberg T; Loman N; Saracco A; von Wachenfeldt A; Rotstein S; Bergqvist M; Bergh J; Hatschek T; Foukakis T
Article: NPJ BREAST CANCER. 2021;7(1):21

Risk of hematologic malignancies after breast ductal carcinoma in situ treatment with ionizing radiation.

Wang K; Li Z; Chen X; Zhang J; Xiong Y; Zhong G; Shi Y; Li Q; Zhang X; Li H; Xiang T; Foukakis T; Radivoyevitch T; Ren G
Article: ACTA ONCOLOGICA. 2020;59(11):1382-1387

Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience.

Edman Kessler L; Wiklander O; Hamberg E; Bergh J; Foukakis T; Matikas A
Article: ESMO OPEN. 2020;5(6):e001032

PD-1 protein and gene expression as prognostic factors in early breast cancer.

Matikas A; Zerdes I; Lövrot J; Sifakis E; Richard F; Sotiriou C; Rassidakis G; Bergh J; Valachis A; Foukakis T
Article: JAMA ONCOLOGY. 2020;6(10):1581-1588

External Evaluation of 3 Commercial Artificial Intelligence Algorithms for Independent Assessment of Screening Mammograms.

Salim M; Wåhlin E; Dembrower K; Azavedo E; Foukakis T; Liu Y; Smith K; Eklund M; Strand F
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(3):645-651

Chemotherapy use near the end-of-life in patients with metastatic breast cancer.

Edman Kessler L; Sigfridsson J; Hatzidaki D; Bergh J; Foukakis T; Georgoulias V; Matikas A
Article: MOLECULAR ONCOLOGY. 2020;14(5):951-963

Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.

Zerdes I; Sifakis EG; Matikas A; Chrétien S; Tobin NP; Hartman J; Rassidakis GZ; Bergh J; Foukakis T
Article: ANNALS OF ONCOLOGY. 2020;31(5):569-581

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.

Schmid P; Salgado R; Park YH; Muñoz-Couselo E; Kim SB; Sohn J; Im S-A; Foukakis T; Kuemmel S; Dent R; Yin L; Wang A; Tryfonidis K; Karantza V; Cortés J; Loi S
Article: BREAST CANCER RESEARCH AND TREATMENT. 2020;181(1):87-96

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.

Brandberg Y; Johansson H; Hellström M; Gnant M; Möbus V; Greil R; Foukakis T; Bergh J; Swedish Breast Cancer Group, the Austrian Breast,
Article: INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2020;106(5):958-967

Five-Year Results of the Preoperative Accelerated Partial Breast Irradiation (PAPBI) Trial.

Bosma SCJ; Leij F; Vreeswijk S; Maaker MD; Wesseling J; Vijver MVD; Scholten A; Rivera S; Bourgier C; Auzac G; Foukakis T; Lekberg T; Bongard D; Loo C; Rutgers E; Bartelink H; Elkhuizen PHM
Article: CANCER. 2020;126(6):1175-1182

Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial.

Papakonstantinou A; Matikas A; Bengtsson NO; Malmström P; Hedayati E; Steger G; Untch M; Hübbert L; Johansson H; Hellström M; Gnant M; Loibl S; Greil R; Moebus V; Foukakis T; Bergh J
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2020;382(9):810-821

Pembrolizumab for Early Triple-Negative Breast Cancer.

Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J; KEYNOTE-522 Investigators
Article: ACTA ONCOLOGICA. 2020;59(1):75-81

Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer.

Papakonstantinou A; Hedayati E; Hellström M; Johansson H; Gnant M; Steger G; Greil R; Untch M; Moebus V; Loibl S; Foukakis T; Bergh J; Matikas A
Article: NPJ BREAST CANCER. 2020;6:36

Long-term anti-inflammatory diet in relation to improved breast cancer prognosis: a prospective cohort study.

Wang K; Sun J-Z; Wu Q-X; Li Z-Y; Li D-X; Xiong Y-F; Zhong G-C; Shi Y; Li Q; Zheng J; Shivappa N; Hébert JR; Foukakis T; Zhang X; Li H-Y; Xiang T-X; Ren G-S
Article: ONCOLOGIST. 2020;25(1):23-32

Effects of Exercise on Chemotherapy Completion and Hospitalization Rates: The OptiTrain Breast Cancer Trial.

Mijwel S; Bolam KA; Gerrevall J; Foukakis T; Wengström Y; Rundqvist H
Article: CANCERS. 2019;11(10):E1479-1479

STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer.

Zerdes I; Wallerius M; Sifakis EG; Wallmann T; Betts S; Bartish M; Tsesmetzis N; Tobin NP; Coucoravas C; Bergh J; Rassidakis GZ; Rolny C; Foukakis T
Article: BRITISH JOURNAL OF CANCER. 2019;120(10):959-967

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K; Luo W; Colleoni M; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Di Lauro V; Gomez HL; Ruhstaller T; Abdi E; Biganzoli L; Müller B; Barbeaux A; Graas M-P; Rabaglio M; Francis PA; Foukakis T; Pagani O; Graiff C; Vorobiof D; Maibach R; Di Leo A; Gelber RD; Goldhirsch A; Coates AS; Regan MM; Bernhard J; SOLE Investigators
Article: LANCET. 2019;393(10179):1440-1452

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Early Breast Cancer Trialists' Collaborative Group
Article: BREAST CANCER RESEARCH. 2019;21(1):34

The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.

Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Article: ANNALS OF ONCOLOGY. 2019;30(1):109-114

Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: further results from the prospective PANTHER study with focus on obese patients.

Matikas A; Foukakis T; Moebus V; Greil R; Bengtsson N-O; Steger GG; Untch M; Johansson H; Hellström M; Malmström P; Gnant M; Loibl S; Bergh J
Article: BREAST CANCER RESEARCH AND TREATMENT. 2018;172(3):703-712

Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.

Falato C; Taylor SK; Szulkin R; Nordblom A; Eriksson L; Sofiadis A; Fredriksson I; Hartman J; Bergh J; Foukakis T
Article: ONCOIMMUNOLOGY. 2018;7(9):e1466017

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer.

Matikas A; Lövrot J; Ramberg A; Eriksson M; Lindsten T; Lekberg T; Hedenfalk I; Loman N; Bergh J; Hatschek T; Erlandsson A; Foukakis T
Article: CELL. 2018;173(4):879-893.e13

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.

Kim C; Gao R; Sei E; Brandt R; Hartman J; Hatschek T; Crosetto N; Foukakis T; Navin NE
Article: EJNMMI RESEARCH. 2018;8(1):25

Treatment response assessment with (R)-[11CPAQ PET in the MMTV-PyMT mouse model of breast cancer.

Tegnebratt T; Lu L; Eksborg S; Chireh A; Damberg P; Nikkhou-Aski S; Foukakis T; Rundqvist H; Holmin S; Kuiper RV; Samen E
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488

Immune gene expression and response to chemotherapy in advanced breast cancer.

Foukakis T; Lövrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Fernö M; Skoog L; Bergh J; Hatschek T
Article: CLINICAL CANCER RESEARCH. 2017;23(24):7512-7520

Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts.

Lundberg A; Lindström LS; Harrell JC; Falato C; Carlson JW; Wright PK; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Article: CLINICAL CANCER RESEARCH. 2017;23(23):7225-7231

PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.

Tobin NP; Lundberg A; Lindström LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Fernö M; Czene K; Perou CM; Bergh J; Hatschek T; TEX Trialists Group
Article: CANCER CELL. 2017;32(5):669-683.e5

An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression.

Palazon A; Tyrakis PA; Macias D; Veliça P; Rundqvist H; Fitzpatrick S; Vojnovic N; Phan AT; Loman N; Hedenfalk I; Hatschek T; Lövrot J; Foukakis T; Goldrath AW; Bergh J; Johnson RS
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2017;114(45):E9635-E9644

Off-tumor targets compromise antiangiogenic drug sensitivity by inducing kidney erythropoietin production.

Nakamura M; Zhang Y; Yang Y; Sonmez C; Zheng W; Huang G; Seki T; Iwamoto H; Ding B; Yin L; Foukakis T; Hatschek T; Li X; Hosaka K; Li J; Yu G; Wang X; Liu Y; Cao Y
Article: NATURE COMMUNICATIONS. 2017;8(1):228

Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer.

Gao R; Kim C; Sei E; Foukakis T; Crosetto N; Chan L-K; Srinivasan M; Zhang H; Meric-Bernstam F; Navin N
Article: LAKARTIDNINGEN. 2017;114:EEIS

[Chemotherapy and targeted drugs to reinforce each other].

Foukakis T; Bergh J
Article: ONCOTARGET. 2016;7(46):74966-74978

Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes.

Vardaki I; Ceder S; Rutishauser D; Baltatzis G; Foukakis T; Panaretakis T
Article: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2016;316(18):1888-1896

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.

Foukakis T; von Minckwitz G; Bengtsson N-O; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J; Swedish Breast Cancer Group (SweBCG), the German B
Article: CLINICAL CANCER RESEARCH. 2016;22(10):2417-2426

An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors.

Tobin NP; Wennmalm K; Lindström LS; Foukakis T; He L; Genové G; Östman A; Landberg G; Betsholtz C; Bergh J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(14):1573-1579

Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?

Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
Article: MOLECULAR ONCOLOGY. 2016;10(4):517-525

Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse.

Falato C; Tobin NP; Lorent J; Lindström LS; Bergh J; Foukakis T
Article: MOLECULAR ONCOLOGY. 2015;9(7):1384-1391

Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer.

Foukakis T; Lövrot J; Sandqvist P; Xie H; Lindström LS; Giorgetti C; Jacobsson H; Hedayati E; Bergh J
Article: ACTA ONCOLOGICA. 2015;54(4):522-529

A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden.

Kessler L; Falato C; Margolin S; Bergh J; Foukakis T
Article: RADIOTHERAPY AND ONCOLOGY. 2015;114(3):322-327

First results of the preoperative accelerated partial breast irradiation (PAPBI) trial.

van der Leij F; Bosma SCJ; van de Vijver MJ; Wesseling J; Vreeswijk S; Rivera S; Bourgier C; Garbay J-R; Foukakis T; Lekberg T; van den Bongard DHJGD; van Vliet-Vroegindeweij C; Bartelink H; Rutgers EJ; Elkhuizen PHM
Article: BREAST CANCER RESEARCH AND TREATMENT. 2014;147(2):407-414

Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer.

Falato C; Lorent J; Tani E; Karlsson E; Wright PK; Bergh J; Foukakis T
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2014;74(3):549-558

Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide.

von Stedingk H; Xie H; Hatschek T; Foukakis T; Rydén A; Bergh J; Rydberg P
Article: BRITISH JOURNAL OF CANCER. 2014;110(5):1378-1384

Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics.

Colzani E; Johansson ALV; Liljegren A; Foukakis T; Clements M; Adolfsson J; Hall P; Czene K
Article: BMC CANCER. 2013;13:473

Clinical instability of breast cancer markers is reflected in long-term in vitro estrogen deprivation studies.

Milosevic J; Klinge J; Borg A-L; Foukakis T; Bergh J; Tobin NP
Article: JOURNAL OF SURGICAL ONCOLOGY. 2012;106(8):981-986

Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution.

Segerhammar I; Larsson C; Nilsson I-L; Bäckdahl M; Höög A; Wallin G; Foukakis T; Zedenius J
Article: ANNALS OF ONCOLOGY. 2012;23 Suppl 10:x349-x353

When to order a biopsy to characterise a metastatic relapse in breast cancer.

Foukakis T; Åström G; Lindström L; Hatschek T; Bergh J
Article: EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2012;166(4):657-667

Proteomic profiling of follicular and papillary thyroid tumors.

Sofiadis A; Becker S; Hellman U; Hultin-Rosenberg L; Dinets A; Hulchiy M; Zedenius J; Wallin G; Foukakis T; Höög A; Auer G; Lehtiö J; Larsson C
Article: BREAST CANCER RESEARCH AND TREATMENT. 2011;130(2):553-560

Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden.

Foukakis T; Fornander T; Lekberg T; Hellborg H; Adolfsson J; Bergh J
Article: THYROID. 2010;20(10):1067-1076

Proteomic study of thyroid tumors reveals frequent up-regulation of the Ca2+ -binding protein S100A6 in papillary thyroid carcinoma.

Sofiadis A; Dinets A; Orre LM; Branca RM; Juhlin CC; Foukakis T; Wallin G; Höög A; Hulchiy M; Zedenius J; Larsson C; Lehtiö J
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2009;35(2):369-374

Diagnostic and prognostic potential of MIB-1 proliferation index in thyroid fine needle aspiration biopsy.

Sofiadis A; Tani E; Foukakis T; Kjellman P; Skoog L; Höög A; Wallin G; Zedenius J; Larsson C
Article: ENDOCRINE-RELATED CANCER. 2008;15(3):801-815

Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma.

Lee J-J; Au AYM; Foukakis T; Barbaro M; Kiss N; Clifton-Bligh R; Staaf J; Borg A; Delbridge L; Robinson BG; Wallin G; Höög A; Larsson C
Article: JOURNAL OF PATHOLOGY. 2008;215(1):87-96

Frizzled-1 is down-regulated in follicular thyroid tumours and modulates growth and invasiveness.

Ulivieri A; Lavra L; Dominici R; Giacomelli L; Brunetti E; Sciacca L; Trovato M; Barresi G; Foukakis T; Jia-Jing L; Larsson C; Bartolazzi A; Sciacchitano S
Article: ENDOCRINE-RELATED CANCER. 2007;14(2):381-391

A PCR-based expression signature of malignancy in follicular thyroid tumors.

Foukakis T; Gusnanto A; Au AYM; Höög A; Lui W-O; Larsson C; Wallin G; Zedenius J
Article: THYROID. 2007;17(4):289-301

Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.

Lee J-J; Foukakis T; Hashemi J; Grimelius L; Heldin N-E; Wallin G; Rudduck C; Lui W-O; Höög A; Larsson C
Article: ENDOCRINE-RELATED CANCER. 2007;14(1):125-134

The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma.

Geli J; Kiss N; Lanner F; Foukakis T; Natalishvili N; Larsson O; Kogner P; Höög A; Clark GJ; Ekström TJ; Bäckdahl M; Farnebo F; Larsson C
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2006;91(3):1143-1149

The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion.

Foukakis T; Au AYM; Wallin G; Geli J; Forsberg L; Clifton-Bligh R; Robinson BG; Lui W-O; Zedenius J; Larsson C
Article: TUMOR BIOLOGY. 2006;27(4):211-220

Molecular markers for discrimination of benign and malignant follicular thyroid tumors.

Fryknäs M; Wickenberg-Bolin U; Göransson H; Gustafsson MG; Foukakis T; Lee J-J; Landegren U; Höög A; Larsson C; Grimelius L; Wallin G; Pettersson U; Isaksson A
Article: ONCOGENE. 2005;24(8):1467-1476

Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPAR(gamma) fusion oncogene.

Lui W-O; Foukakis T; Lidén J; Thoppe SR; Dwight T; Höög A; Zedenius J; Wallin G; Reimers M; Larsson C
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2005;26(1):141-149

Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors.

Foukakis T; Thoppe SR; Lagercrantz S; Dwight T; Weng W-H; Svensson A; Höög A; Zedenius J; Wallin G; Lui W-O; Larsson C
Article: JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2003;88(9):4440-4445

Involvement of the PAX8/peroxisome proliferator-activated receptor gamma rearrangement in follicular thyroid tumors.

Dwight T; Thoppe SR; Foukakis T; Lui WO; Wallin G; Höög A; Frisk T; Larsson C; Zedenius J
Article: GENES CHROMOSOMES & CANCER. 2002;35(1):74-80

Silencing of the PTEN tumor-suppressor gene in anaplastic thyroid cancer.

Frisk T; Foukakis T; Dwight T; Lundberg J; Höög A; Wallin G; Eng C; Zedenius J; Larsson C
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 1992;33(4):861-869

Gene-specific promoter hypermethylation without global hypomethylation in follicular thyroid cancer.

Lee J-J; Geli J; Larsson C; Wallin G; Karimi M; Zedenius J; Höög A; Foukakis T
Visa fler

Alla övriga publikationer

Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2023;192:104189

The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review.

Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Editorial comment: MOLECULAR ONCOLOGY. 2023;17(4):545-547

The interplay between eosinophils and T cells in breast cancer immunotherapy.

Zerdes I; Matikas A; Foukakis T
Review: JOURNAL OF IMAGING. 2022;8(11):303

Harmonization Strategies in Multicenter MRI-Based Radiomics.

Stamoulou E; Spanakis C; Manikis GC; Karanasiou G; Grigoriadis G; Foukakis T; Tsiknakis M; Fotiadis DI; Marias K
Review: CANCERS. 2022;14(8):1999

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution.

Tzoras E; Zerdes I; Tsiknakis N; Manikis GC; Mezheyeuski A; Bergh J; Matikas A; Foukakis T
Review: FRONTIERS IN ONCOLOGY. 2022;12:999843

Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis.

Zhu Y; Tzoras E; Matikas A; Bergh J; Valachis A; Zerdes I; Foukakis T
Editorial comment: ANNALS OF ONCOLOGY. 2021;32(12):1457-1459

Adjuvant abemaciclib for high-risk breast cancer: the story continues.

Spring L; Matikas A; Bardia A; Foukakis T
Review: ESMO OPEN. 2021;6(6):100289

The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis.

Paakkola N-M; Karakatsanis A; Mauri D; Foukakis T; Valachis A
Review: CANCER TREATMENT REVIEWS. 2021;99:102257

Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis.

Boman C; Zerdes I; Mårtensson K; Bergh J; Foukakis T; Valachis A; Matikas A
Corrigendum: JAMA ONCOLOGY. 2021;7(9):1405-1406

Errors in Abstract and Results.
Editorial comment: BREAST CARE. 2021;16(4):422-428

Expert Discussion: HER2-Positive Breast Cancer.

Foukakis T; Matikas A; Oikonomidou O; Andreopoulou E; Mavroudis D
Editorial comment: ANNALS OF ONCOLOGY. 2021;32(2):129-132

SOLAR1s: alpelisib returns to earth?

Matikas A; Foukakis T
Corrigendum: BRITISH JOURNAL OF CANCER. 2020;122(7):1119

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi K; Luo W; Colleoni M; Karlsson P; Chirgwin J; Aebi S; Jerusalem G; Neven P; Di Lauro V; Gomez HL; Ruhstaller T; Abdi E; Biganzoli L; Müller B; Barbeaux A; Graas M-P; Rabaglio M; Francis PA; Foukakis T; Pagani O; Graiff C; Vorobiof D; Maibach R; Di Leo A; Gelber RD; Goldhirsch A; Coates AS; Regan MM; Bernhard J; SOLE Investigators
Review: CLINICAL CANCER RESEARCH. 2019;25(18):5717-5726

Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.

Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
Review: ANNALS OF ONCOLOGY. 2019;30(7):1044-1050

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?

Matikas A; Foukakis T; Swain S; Bergh J
Review: CANCERS. 2019;11(5):E628-628

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy.

Chrétien S; Zerdes I; Bergh J; Matikas A; Foukakis T
Editorial comment: JOURNAL OF INTERNAL MEDICINE. 2019;285(4):395-397

Minimally invasive tissue access as a tool for delivering personalized medicine - with focus on oncology.

Matikas A; Foukakis T; Bergh J
Editorial comment: ANNALS OF ONCOLOGY. 2018;29(12):2278-2280

Carboplatin in the neoadjuvant treatment of triple-negative breast cancer-ready for prime time?

Foukakis T
Letter: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(11):1280-1281

RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis.

Matikas A; Foukakis T; Bergh J
Review: ONCOGENE. 2018;37(34):4639-4661

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.

Zerdes I; Matikas A; Bergh J; Rassidakis GZ; Foukakis T
Editorial comment: LANCET ONCOLOGY. 2018;19(7):850-852

Ribociclib in premenopausal women with advanced breast cancer.

Foukakis T
Published conference paper: BREAST CANCER RESEARCH AND TREATMENT. 2018;168(2):349-355

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer.

Matikas A; Margolin S; Hellström M; Johansson H; Bengtsson N-O; Karlsson L; Edlund P; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmstrom P; Villman K; Foukakis T; Bergh J
Review: ACTA ONCOLOGICA. 2017;56(9):1143-1151

Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts.

Matikas A; Foukakis T; Bergh J
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2017;114:91-101

Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine.

Matikas A; Foukakis T; Bergh J
Review: EXPERT REVIEW OF ANTICANCER THERAPY. 2017;17(4):319-326

Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer.

Matikas A; Foukakis T; Michalakis I; Georgoulias V
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2017;35(1):121-122

Reply to A.Y. Lin.

Papakonstantinou A; Foukakis T; Rodriguez-Wallberg KA; Bergh J
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2016;374(14):1386-1387

A 21-Gene Expression Assay in Breast Cancer.

Foukakis T; Falato C; Bergh J
Review: JOURNAL OF INTERNAL MEDICINE. 2015;278(6):545-570

The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer.

Tobin NP; Foukakis T; De Petris L; Bergh J
Letter: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(1):84-85

Thyroid hormone inactivation in gastrointestinal stromal tumors.

Foukakis T; Lövrot J; Bergh J
Review: ACTA ONCOLOGICA. 2007;46(3):277-285

Advances in the treatment of patients with gastric adenocarcinoma.

Foukakis T; Lundell L; Gubanski M; Lind PA
Visa fler

Anställningar

Universitetslektor/Överläkare, Onkologi-Patologi, Karolinska Institutet, 2020-

Examina och utbildning

Docent, Onkologi, Karolinska Institutet, 2014
MEDICINE DOKTORSEXAMEN, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2005

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI